Ziopharm Oncology, Inc. (ZIOP) Posts Q3 Loss of 6c/Share

Ziopharm Oncology, Inc. (NASDAQ: ZIOP) reported Q3 EPS of ($0.06), which may not compare with the analyst estimate of ($0.12). Revenue for the quarter came in at $633 thousand versus the consensus estimate of $3.43 million.

Included in the loss for the third quarter of 2014 was a non-cash gain of $5.8 million compared to a non-cash loss of $7.4 million for the third quarter of 2013. The non-cash gain/loss is related to the change in the fair value of the company's outstanding liability-classified warrants.

For earnings history and earnings-related data on Ziopharm Oncology, Inc. (ZIOP) click here.

You May Also Be Interested In

• VNET Group (VNET) Misses Q2 EPS by 164c
• Pony AI (PONY) Reports Revenue Above Estimates
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance